PLK1 and breast cancer: MYC-driven breast cancer is shown to be more responsive to PDK1/PLK1 inhibitors than is MYC-independent one, and taking into consideration that a MYC inhibitor is not currently available in the clinic, targeting the PDK1-PLK1-MYC axis reveals a new potential therapeutic approach against MYC-induced cancers.